by John Conrad | Oct 28, 2024 | Member News, NewsBrief
Chicago-headquartered Iterum Therapeutics (Nasdaq: ITRM) has received U.S. Food and Drug Administration (FDA) approval for ORLYNVAH™ (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women with limited...
